[go: up one dir, main page]

NO321707B1 - Isolert DNA som koder for et TRAIL-polypeptid og et opploselig TRAIL-polypeptid, ekspresjonsvektor, fremgangsmate for fremstilling av et TRAIL-polypeptid, isolert DNA som koder for et fusjonsprotein, fremgangsmate for fremstilling av en TRAIL-oligomer, antistoff som binder et TRAIL-polypeptid, renset TRAIL-polypeptid og opploselig TRAIL-polypeptid, oligomer, farmasoytisk preparat, farmasoytisk preparat for bruk som et medikament, farmasoytisk preparat for anvendelse ved indusering av apoptose hos malceller samt anvendelse av et TRAIL-polypeptid ved fremstilling av et medikament. - Google Patents

Isolert DNA som koder for et TRAIL-polypeptid og et opploselig TRAIL-polypeptid, ekspresjonsvektor, fremgangsmate for fremstilling av et TRAIL-polypeptid, isolert DNA som koder for et fusjonsprotein, fremgangsmate for fremstilling av en TRAIL-oligomer, antistoff som binder et TRAIL-polypeptid, renset TRAIL-polypeptid og opploselig TRAIL-polypeptid, oligomer, farmasoytisk preparat, farmasoytisk preparat for bruk som et medikament, farmasoytisk preparat for anvendelse ved indusering av apoptose hos malceller samt anvendelse av et TRAIL-polypeptid ved fremstilling av et medikament. Download PDF

Info

Publication number
NO321707B1
NO321707B1 NO19976045A NO976045A NO321707B1 NO 321707 B1 NO321707 B1 NO 321707B1 NO 19976045 A NO19976045 A NO 19976045A NO 976045 A NO976045 A NO 976045A NO 321707 B1 NO321707 B1 NO 321707B1
Authority
NO
Norway
Prior art keywords
trail
polypeptide
seq
trail polypeptide
cells
Prior art date
Application number
NO19976045A
Other languages
English (en)
Norwegian (no)
Other versions
NO976045D0 (no
NO976045L (no
Inventor
Raymond G Goodwin
Steven R Wiley
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27052201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO321707(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO976045D0 publication Critical patent/NO976045D0/no
Publication of NO976045L publication Critical patent/NO976045L/no
Publication of NO321707B1 publication Critical patent/NO321707B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L27/00—Modulated-carrier systems
    • H04L27/18—Phase-modulated carrier systems, i.e. using phase-shift keying
    • H04L27/22—Demodulator circuits; Receiver circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19976045A 1995-06-29 1997-12-22 Isolert DNA som koder for et TRAIL-polypeptid og et opploselig TRAIL-polypeptid, ekspresjonsvektor, fremgangsmate for fremstilling av et TRAIL-polypeptid, isolert DNA som koder for et fusjonsprotein, fremgangsmate for fremstilling av en TRAIL-oligomer, antistoff som binder et TRAIL-polypeptid, renset TRAIL-polypeptid og opploselig TRAIL-polypeptid, oligomer, farmasoytisk preparat, farmasoytisk preparat for bruk som et medikament, farmasoytisk preparat for anvendelse ved indusering av apoptose hos malceller samt anvendelse av et TRAIL-polypeptid ved fremstilling av et medikament. NO321707B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49663295A 1995-06-29 1995-06-29
US54836895A 1995-11-01 1995-11-01
PCT/US1996/010895 WO1997001633A1 (fr) 1995-06-29 1996-06-25 Cytokine inductrice d'apoptose

Publications (3)

Publication Number Publication Date
NO976045D0 NO976045D0 (no) 1997-12-22
NO976045L NO976045L (no) 1998-03-02
NO321707B1 true NO321707B1 (no) 2006-06-26

Family

ID=27052201

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19976045A NO321707B1 (no) 1995-06-29 1997-12-22 Isolert DNA som koder for et TRAIL-polypeptid og et opploselig TRAIL-polypeptid, ekspresjonsvektor, fremgangsmate for fremstilling av et TRAIL-polypeptid, isolert DNA som koder for et fusjonsprotein, fremgangsmate for fremstilling av en TRAIL-oligomer, antistoff som binder et TRAIL-polypeptid, renset TRAIL-polypeptid og opploselig TRAIL-polypeptid, oligomer, farmasoytisk preparat, farmasoytisk preparat for bruk som et medikament, farmasoytisk preparat for anvendelse ved indusering av apoptose hos malceller samt anvendelse av et TRAIL-polypeptid ved fremstilling av et medikament.

Country Status (15)

Country Link
US (1) US5763223A (fr)
EP (2) EP0835305B1 (fr)
JP (1) JP4435304B2 (fr)
KR (2) KR100510234B1 (fr)
AT (2) ATE310813T1 (fr)
AU (1) AU708239B2 (fr)
CA (1) CA2225378C (fr)
DE (2) DE69638346D1 (fr)
DK (2) DK0835305T3 (fr)
ES (2) ES2253753T3 (fr)
IL (6) IL149261A0 (fr)
NO (1) NO321707B1 (fr)
NZ (1) NZ311982A (fr)
PT (1) PT1666591E (fr)
WO (1) WO1997001633A1 (fr)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715645B2 (en) * 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US20040038347A1 (en) * 1996-03-14 2004-02-26 Human Genome Sciences, Inc. Apoptosis inducing molecule I
WO1997046686A2 (fr) * 1996-06-07 1997-12-11 Amgen Inc. Polypeptide apparente au facteur de necrose tumorale
US6017729A (en) * 1996-12-23 2000-01-25 Immunex Corporation Receptor activator of NF-κB
US8329179B2 (en) * 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7452538B2 (en) * 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
JP4450870B2 (ja) * 1997-01-28 2010-04-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター４（ｄｒ４：死レセプター４）、ｔｎｆ−レセプタースーパーファミリーのメンバーおよびｔｒａｉｌへの結合
US6433147B1 (en) * 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US20020009467A1 (en) 1997-01-29 2002-01-24 Shozo Koyama Antigenic substance inductor, vaccine precursor, vaccine, antibody, neutralizing antibody, antitoxin, idiotype antibody and/or anti-idiotype antibody which is induced by its idiotype antibody
JP3813682B2 (ja) * 1997-01-29 2006-08-23 小山 省三 ワクチン前駆体およびワクチン
WO1998035061A2 (fr) * 1997-02-12 1998-08-13 Abbott Laboratories Element de la famille tnf utilise pour le traitement et le diagnostic d'une maladie
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US7528239B1 (en) * 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
DE69836956T2 (de) * 1997-03-17 2007-10-31 Human Genome Sciences, Inc. Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
JP2001526532A (ja) 1997-04-16 2001-12-18 アムジエン・インコーポレーテツド オステオプロテゲリン結合性蛋白および受容体
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
IL132067A0 (en) * 1997-05-15 2001-03-19 Genentech Inc Apo-2 receptor
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
IL133122A0 (en) * 1997-06-18 2001-03-19 Genentech Inc Apo-2dcr polypeptides
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
WO1999002653A1 (fr) * 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Acide nucleique codant une nouvelle proteine induite par chimiotherapie, et ses procedes d'utilisation
FR2766713B1 (fr) * 1997-08-04 1999-09-24 Bio Merieux Facteur proteique associe a une maladie neuro-degenerative et/ou auto-immune et/ou inflammatoire
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
AU5201399A (en) 1997-09-30 1999-10-18 Pharmacia & Upjohn Company Tnf-related death ligand
JP4485049B2 (ja) * 1997-11-18 2010-06-16 ジェネンテック， インコーポレイテッド Ｄｎａ１９３５５ポリペプチドという腫瘍壊死因子相同体
US7019119B2 (en) * 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
DK1045906T3 (da) * 1998-01-15 2009-02-16 Genentech Inc APO-2-ligand
US20040120947A1 (en) * 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
US20040180049A1 (en) * 1998-01-26 2004-09-16 Genentech, Inc. DR4 antibodies and uses thereof
EP2050762A3 (fr) 1998-03-10 2009-07-08 Genentech, Inc. Nouvelles polypeptides et acides nucléiques les codant
ES2308836T3 (es) * 1998-03-27 2008-12-01 Genentech, Inc. Sinergia de los anticuerpos anti-her-2 y de los ligands para l'apo-2.
EP1941905A1 (fr) 1998-03-27 2008-07-09 Genentech, Inc. Synergie d'anticorps APO-2 ligand-anti-her-2
PT1086138E (pt) * 1998-06-12 2010-01-04 Genentech Inc Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
NZ508950A (en) 1998-07-13 2003-10-31 Univ Texas Cancer treatment methods using antibodies to aminophospholipids
EP1129102A1 (fr) * 1998-11-02 2001-09-05 Clontech Laboratories Inc. Gene et proteine regulant la mort cellulaire
US20030187196A1 (en) * 1998-12-30 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
US6534061B1 (en) 1999-04-12 2003-03-18 Genentech, Inc. Tumor necrosis factor receptor homologs and nucleic acids encoding the same
AU3923000A (en) * 1999-04-16 2000-11-02 Amgen, Inc. Agp-1 fusion protein compositions and methods
EP1867719A3 (fr) * 1999-06-02 2008-03-19 Genentech, Inc. Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
KR100674528B1 (ko) * 1999-06-28 2007-01-29 제넨테크, 인크. 2가 금속 이온을 사용한 Ａｐｏ-2 리간드 제조 방법
US6444640B1 (en) * 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof
EP1223961A4 (fr) * 1999-09-30 2005-10-05 Univ Pennsylvania "trail" en tant qu'inhibiteur de l'inflammation auto-immune et de la progression du cycle cellulaire
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
US7927602B2 (en) * 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
AU784614B2 (en) * 2000-01-24 2006-05-11 University Of Louisville Research Foundation, Inc. Immune modulation with death receptor-induced apoptosis
PT1255558E (pt) 2000-02-16 2006-11-30 Genentech Inc Anticorpos anti-april e células hibridoma
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US6900185B1 (en) 2000-04-12 2005-05-31 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
CA2413237C (fr) 2000-06-30 2013-09-10 University Of Louisville Research Foundation, Inc. Alteration des membranes cellulaires en vue d'obtenir de nouvelles fonctions
CA2415473A1 (fr) 2000-07-27 2002-02-07 Genentech, Inc. Synergisme de l'agoniste du recepteur de l'apo-2l et du cpt-11
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
KR20030055274A (ko) 2000-10-20 2003-07-02 츄가이 세이야꾸 가부시키가이샤 저분자화 트롬보포에틴 아고니스트 항체
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
AU2001297702A1 (en) * 2000-11-08 2002-10-15 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20020155109A1 (en) * 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
CN100594935C (zh) 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
GB0113920D0 (en) * 2001-06-07 2001-08-01 Sterix Ltd Composition
EP2087908B1 (fr) 2001-06-26 2018-05-30 Amgen Inc. Anticorps opgl
DK1409544T3 (da) 2001-07-03 2009-10-26 Genentech Inc Humane DR4-antistoffer og anvendelser deraf
US20030082722A1 (en) * 2001-08-08 2003-05-01 Bingliang Fang Method for amplifying expression from a cell specific promoter
CA2461292A1 (fr) * 2001-10-02 2003-04-10 Genentech, Inc. Variants de ligands apo-2 et leurs utilisations
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
DK1450847T3 (da) 2001-11-13 2010-12-13 Genentech Inc Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
AU2007200478A1 (en) * 2001-11-13 2007-02-22 Genentech, Inc. APO2 ligand/trail formulations
US20030180296A1 (en) * 2001-12-20 2003-09-25 Theodora Salcedo Antibodies that immunospecifically bind to trail receptors
PL376821A1 (pl) 2002-03-27 2006-01-09 Immunex Corporation Sposoby zwiększania produkcji polipeptydów
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
AU2003247609A1 (en) 2002-06-24 2004-01-06 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
DK2269656T3 (da) 2002-07-15 2014-11-03 Univ Texas Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer
AU2003296310A1 (en) * 2002-12-06 2004-06-30 University Of South Florida Histone deacetylase inhibitor enhancement of trail-induced apoptosis
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
EP1667720A1 (fr) * 2003-09-18 2006-06-14 Novartis AG Combinaison d'un inhibiteur de l'histone desacetylase avec un ligand des recepteurs de mort
EP1688498B1 (fr) 2003-11-03 2011-03-09 Beijing Sunbio Biotech Co., Ltd. Proteine de recombinaison anticancereuse, ses genes codant et ses utilisations
US20080206229A1 (en) 2003-12-12 2008-08-28 Koichiro Ono Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
CN1953743B (zh) 2004-01-22 2010-12-08 迈阿密大学 局部辅酶q10制剂及其使用方法
US20080242603A1 (en) * 2004-02-20 2008-10-02 Yan Wang Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
AU2005222397A1 (en) 2004-03-11 2005-09-22 Genentech, Inc. Process for producing polypeptides
NZ550518A (en) 2004-03-23 2009-11-27 Biogen Idec Inc Agents that cross link TNF receptors for treating cancer
EP1778871B1 (fr) 2004-08-06 2011-05-04 Genentech, Inc. Tests et methodes comprenant l'utilisation de marqueurs biologiques
DK1774037T3 (da) 2004-08-06 2011-08-15 Genentech Inc Analyser og fremgangsmåder, der anvender biomarkører
MX2007002855A (es) * 2004-09-08 2007-04-27 Genentech Inc Metodos para usar ligandos de receptor de muerte y anticuerpos cd20.
BRPI0515604A (pt) * 2004-09-08 2008-07-29 Genentech Inc método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada
EP1645875A1 (fr) * 2004-10-08 2006-04-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic et thérapie de cellules cancéreuses à partir de la résistance à l'apoptose conférée par TRAIL
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060228352A1 (en) * 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
JP2006265155A (ja) * 2005-03-23 2006-10-05 Link Genomics Kk 癌の免疫療法
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
EP1908482B1 (fr) 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilisant pour une préparation de protéine contenant de la méglumine et son utilisation
EP2287615A1 (fr) 2005-08-16 2011-02-23 Genentech, Inc. GALNAC-T14 expression comme test pour la sensibilité d'apoptose de cellules à APO2L/TRAIL
CA2619654A1 (fr) * 2005-08-24 2007-03-01 Cell Matrix Therapies combinees visant a inhiber les interactions integrine-matrice extracellulaire
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
WO2008008155A2 (fr) * 2006-06-20 2008-01-17 The Trustees Of The University Of Pennsylvania Modulateurs à petites cellules du signalement de la famille p53
WO2008088582A2 (fr) * 2006-08-04 2008-07-24 Mayo Foundation For Medical Education And Research Méthodes et substances associées à des isoformes trail
CA2963124C (fr) 2007-07-10 2019-10-15 Apogenix Ag Proteines de fusion collectines de la superfamille des tnf
AU2013203061B2 (en) * 2007-07-10 2016-07-28 Apogenix Ag TNF superfamily collectin fusion proteins
WO2009025743A2 (fr) * 2007-08-17 2009-02-26 University Of Massachusetts Medical School Utilisation de compositions trail en tant qu'agents antiviraux
CN101157729B (zh) * 2007-10-23 2011-01-12 南京大学 一种肿瘤坏死因子相关凋亡配体变体及其应用
BRPI0820298A8 (pt) 2007-11-09 2018-05-08 Affitech Res As composições e métodos de anticorpos anti-vegf
BRPI0921837A2 (pt) 2008-11-25 2016-01-12 Biogen Idec Inc anticorpos isolados ou fragmentos de antígeno de ligação dos mesmos que podem se ligar especificamente a um polipeptídio dr6, métodos in vitro de promover a sobrevivência de uma célula do sistema nervoso, usos de um antagonista dr6 e métodos in vitro de inibir a ligação de dr6 com p75
EP2382236B1 (fr) 2009-01-09 2016-08-17 Apogenix AG Protéines de fusion formant des trimères
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
ES2356880B8 (es) 2009-08-21 2012-10-30 Universidad De Zaragoza Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail.
CN102686606A (zh) * 2009-10-09 2012-09-19 阿纳福公司 结合il-23r的多肽
US8703732B2 (en) * 2010-04-01 2014-04-22 Korea Research Institute Of Bioscience And Biotech Composition for enhancing TRAIL sensitivity comprising inhibitors for expression or activity of TIP41 as a target gene of TRAIL sensitizer
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
WO2012019160A1 (fr) 2010-08-05 2012-02-09 Amgen Inc. Dipeptides pour améliorer le rendement et la viabilité de cultures cellulaires
PT2646464E (pt) 2010-12-03 2015-10-05 Adamed Sp Zoo Proteína de fusão anticancerígena
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
PL394618A1 (pl) 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
JP2014513128A (ja) 2011-05-03 2014-05-29 ジェネンテック， インコーポレイテッド 血管破壊剤とその使用
KR102761360B1 (ko) 2011-07-01 2025-02-05 암젠 인크 포유동물 세포 배양
CN102908612A (zh) * 2011-08-02 2013-02-06 北京诺赛基因组研究中心有限公司 TRAIL截短型变异体活化NF-κB和在炎症反应中的应用
US20140315187A1 (en) 2011-09-02 2014-10-23 Amgen Inc. Pharmaceutical Product and Method of Analysing Light Exposure of a Pharmaceutical Product
WO2013037090A1 (fr) * 2011-09-16 2013-03-21 北京沙东生物技术有限公司 Protéine de fusion comprenant une forme permutée circulairement de trail/apo2l, gène codant et utilisation de ladite protéine
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
PL223487B1 (pl) 2011-12-28 2016-10-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
CN104918622A (zh) * 2012-12-11 2015-09-16 赛博尔泰克股份公司 用于对抗黑色素瘤细胞的飞燕草素
WO2014109858A1 (fr) 2013-01-14 2014-07-17 Amgen Inc. Méthodes d'utilisation d'inhibiteurs de cycle cellulaire pour moduler une ou plusieurs propriétés d'une culture cellulaire
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
LT2970473T (lt) 2013-03-14 2017-10-25 Bristol-Myers Squibb Company Dr5 agonisto ir anti-pd-1 antagonisto derinys ir naudojimo būdai
CA2904411A1 (fr) 2013-03-14 2014-10-02 Amgen Inc. Elimination de ligand de purification d'affinite ayant fui
TWI625390B (zh) 2013-03-14 2018-06-01 安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
KR20160030099A (ko) 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
CN103555729B (zh) * 2013-10-14 2016-08-24 成都华创生物技术有限公司 一种改造的trail基因序列、表达方法及应用
EP4589002A2 (fr) 2013-10-31 2025-07-23 Amgen Inc. Utilisation de monensine dans la régulation de la glycosylation des protéines recombinantes
SG11201605640UA (en) 2014-01-13 2016-08-30 Amgen Inc Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
BR112016017606A2 (pt) 2014-01-29 2017-10-10 Amgen Inc superexpressão de reguladores de via de n-glicosilação para modular a glicosilação de proteínas recombinantes
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
WO2015138638A1 (fr) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Agonistes de récepteur de protéine trail à action prolongée pour le traitement de maladies auto-immunes
TR201900776T4 (tr) 2014-06-04 2019-02-21 Amgen Inc Memeli hücre kültürlerinin hasadına ilişkin yöntem.
AU2015349809B2 (en) 2014-11-19 2022-02-10 Amgen Inc. Quantitation of glycan moiety in recombinant glycoproteins
MX385409B (es) 2014-12-01 2025-03-04 Amgen Inc Proceso para manipular el nivel de contenido de glicano de una glicoproteína.
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
ES3013312T3 (en) 2015-12-17 2025-04-11 Univ Johns Hopkins Ameliorating systemic sclerosis with death receptor agonists
CN108472379B (zh) 2015-12-30 2022-06-21 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂
JP6725699B2 (ja) * 2016-02-05 2020-07-22 エスエルビゲン・インコーポレイテッドＳｌｂｉｇｅｎ Ｉｎｃ． Ｔｒａｉｌとｃｄを発現している間葉系幹細胞およびその使用
JP7281795B2 (ja) 2016-04-07 2023-05-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
KR101739703B1 (ko) * 2016-09-13 2017-05-24 (주) 어드밴스드 엔티 Trail 기반 뇌염 감별진단 방법 및 장치
IL321253A (en) 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
US11519007B2 (en) 2019-02-22 2022-12-06 Arizona Board Of Regents On Behalf Of Arizona State University Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy
WO2023129974A1 (fr) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Génération de lignées de cellules avec site d'intégration

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
EP0276846A3 (fr) 1987-01-29 1989-07-26 Zymogenetics, Inc. Dérivés du facteur stimulant des colonies
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
ES2055907T3 (es) 1989-03-07 1994-09-01 Genentech Inc Conjugados covalentes de lipidos y oligonucleotidos.
JPH04505261A (ja) 1989-05-10 1992-09-17 スローン―ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ ポルｉｉｉプロモーターの制御下の転写可能な外来ｄｎａを含む安定的に形質転換された真核細胞
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
WO1991004753A1 (fr) 1989-10-02 1991-04-18 Cetus Corporation Conjugues d'oligonucleotides non codants et leurs emplois therapeutiques
AU653504B2 (en) 1989-10-24 1994-10-06 Isis Pharmaceuticals, Inc. Oligonucleotide analogs with novel linkages
WO1991018982A1 (fr) 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
AU678787B2 (en) 1992-10-23 1997-06-12 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5512435A (en) * 1993-02-05 1996-04-30 Renschler; Markus F. Receptor-binding antiproliferative peptides
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JPH09503672A (ja) 1993-10-14 1997-04-15 イミュネックス・コーポレーション Ｆａｓ拮抗剤とその利用
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
WO1997033899A1 (fr) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Molecule i induisant l'apoptose
WO1997046686A2 (fr) * 1996-06-07 1997-12-11 Amgen Inc. Polypeptide apparente au facteur de necrose tumorale

Also Published As

Publication number Publication date
EP0835305B1 (fr) 2005-11-23
IL184699A (en) 2011-11-30
IL122408A0 (en) 1998-06-15
DE69635480T2 (de) 2006-08-17
KR100510234B1 (ko) 2005-11-25
NO976045D0 (no) 1997-12-22
ATE310813T1 (de) 2005-12-15
AU6340796A (en) 1997-01-30
NO976045L (no) 1998-03-02
AU708239B2 (en) 1999-07-29
DE69638346D1 (de) 2011-05-05
IL149261A0 (en) 2002-11-10
IL184699A0 (en) 2007-12-03
PT1666591E (pt) 2011-06-01
CA2225378C (fr) 2012-04-17
NZ311982A (en) 1999-08-30
JP4435304B2 (ja) 2010-03-17
CA2225378A1 (fr) 1997-01-16
IL122408A (en) 2008-03-20
WO1997001633A1 (fr) 1997-01-16
DK1666591T3 (da) 2011-05-23
ES2362191T3 (es) 2011-06-29
ES2253753T3 (es) 2006-06-01
DK0835305T3 (da) 2006-02-13
EP1666591A1 (fr) 2006-06-07
KR19990028264A (ko) 1999-04-15
HK1010215A1 (en) 1999-06-17
JPH11508445A (ja) 1999-07-27
HK1092836A1 (en) 2007-02-16
KR101004174B1 (ko) 2010-12-24
IL149261A (en) 2006-09-05
IL190068A0 (en) 2008-08-07
EP0835305A4 (fr) 2002-02-06
MX9710399A (es) 1998-03-31
DE69635480D1 (de) 2005-12-29
KR20050085914A (ko) 2005-08-29
ATE503013T1 (de) 2011-04-15
US5763223A (en) 1998-06-09
EP0835305A1 (fr) 1998-04-15
EP1666591B1 (fr) 2011-03-23

Similar Documents

Publication Publication Date Title
NO321707B1 (no) Isolert DNA som koder for et TRAIL-polypeptid og et opploselig TRAIL-polypeptid, ekspresjonsvektor, fremgangsmate for fremstilling av et TRAIL-polypeptid, isolert DNA som koder for et fusjonsprotein, fremgangsmate for fremstilling av en TRAIL-oligomer, antistoff som binder et TRAIL-polypeptid, renset TRAIL-polypeptid og opploselig TRAIL-polypeptid, oligomer, farmasoytisk preparat, farmasoytisk preparat for bruk som et medikament, farmasoytisk preparat for anvendelse ved indusering av apoptose hos malceller samt anvendelse av et TRAIL-polypeptid ved fremstilling av et medikament.
US6284236B1 (en) Cytokine that induces apoptosis
NO320354B1 (no) Anvendelse av et CD40-bindende protein som har evne til a binde CD40 og hindrer binding av CD40 til CD40-L ved fremstilling av et middel for forebyggelse eller behandling av en neoplasmatisk sykdom.
KR20180057723A (ko) 항-cd30 키메라성 항원 수용체
NO20111232A1 (no) BAFF-reseptor (BCMA), et immunoregulatorisk middel
JP2002509430A (ja) Ｔｎｆスーパーファミリーのメンバーであるｎｆ−ｋａｐｐａ ｂの受容体アクティベーターに対するリガンド
WO1996029348A1 (fr) Anticorps monoclonal dirige contre la proteine receptrice 4-1bb d'origine humaine et procedes d'utilisation de cet anticorps pour le traitement des maladies
CN109265565A (zh) 一种携带分子开关的抗CD79b嵌合抗原受体及其修饰的免疫细胞和应用
JP2002507127A (ja) Ｔｒａｉｌに結合するタンパク質
US9920119B2 (en) Chimeric molecule involving oligomerized FasL extracellular domain
WO2021151001A1 (fr) Polypeptides chimères
AU724826B2 (en) Cytokine that includes apoptosis
US20230159615A1 (en) Chimeric polypeptides
HK1010215B (en) Cytokine that induces apoptosis
MXPA97010399A (es) Citocina que induce apoptosis
HK1092836B (en) Cytokine that induces apoptosis

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees